GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are reshaping the landscape of weight management and metabolic health. These drugs, originally developed for diabetes, have proven remarkably effective in helping people lose weight, regulate blood sugar, and reduce risks associated with obesity-related conditions. Yet, while the promise is enormous, the first 90 days of treatment often feel like a hidden battlefield that few talk about openly. This early phase is where most challenges arise, and unfortunately, it’s also when many patients decide to quit.
The reality is that side effects like nausea, fatigue, constipation, or food aversion can be overwhelming. For some, even the smell of certain foods becomes intolerable. Others struggle with the sudden shift in appetite, unsure how to balance nutrition when their body no longer craves the same meals. These physical changes are compounded by emotional and social hurdles: unsolicited comments from coworkers about weight loss, awkward questions from friends, or the quiet anxiety of wondering whether what you’re experiencing is “normal.” Between monthly appointments, patients often feel stranded, left to Google symptoms or second-guess whether they should continue. This gap in support is one of the biggest reasons adherence falters.
Statistics show that one in three people stop GLP-1 therapy within the first 90 days. What’s striking is that most of these dropouts are preventable. With better education, proactive management of side effects, and stronger support systems, many of these early struggles could be eased. For example, nausea can often be managed with small dietary adjustments—like eating bland foods, avoiding greasy meals, or spacing out smaller portions throughout the day. Fatigue may improve with hydration, gentle exercise, and adequate sleep. Even food aversion, though frustrating, can be navigated by experimenting with new flavors and textures that feel tolerable. These are not insurmountable barriers; they are manageable challenges if patients are guided through them.
Beyond the physical, there’s a psychological dimension. The journey with GLP-1s is not just about losing weight—it’s about reshaping habits, identity, and relationships with food. Patients need reassurance that setbacks are part of the process, not signs of failure. They need communities where they can share experiences without judgment, and healthcare providers who check in more frequently during those crucial first months. The difference between quitting and succeeding often comes down to feeling supported rather than isolated.
The message is clear: the first 90 days matter more than anyone admits. If we can normalize the struggles, provide practical coping strategies, and close the gap between appointments, we can dramatically reduce dropout rates. GLP-1 medications are powerful tools, but tools only work when people can use them consistently. Let’s change the narrative from silent suffering to shared solutions. Let’s ensure that patients don’t just start these medications—they thrive on them. Because when the first 90 days are managed well, the long-term benefits can be life-changing.
